New product intros [berotralstat hydrochloride, cetuximab sarotalocan, daratumumab sc (new indication), eptacog beta, coagulation factor VIIa-jncw, etesevimab, evinacumab-dgnb (first-in-class), human SARS-CoV-2 inactivated vaccine, inclisiran, orelabrutinib, relugolix (new indication), remogliflozin etabonate/vildagliptin (new combination), surufatinib, voclosporin].

• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 3, 2021, págs. 241-245
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • berotralstat hydrochloride, cetuximab sarotalocan, daratumumab sc (new indication), eptacog beta, coagulation factor VIIa-jncw, etesevimab, evinacumab-dgnb (first-in-class), human SARS-CoV-2 inactivated vaccine, inclisiran, orelabrutinib, relugolix (new indication), remogliflozin etabonate/vildagliptin (new combination), surufatinib, voclosporin